About Therapix Biosciences
Therapix Biosciences is a Healthcare company based in Givatayim (Israel) founded in 2014, and was acquired by FSD Pharma in October 2018. Cannabinoid-based therapies for central nervous system disorders are developed. Its chief executive, as recorded, is Amitay Weiss. Its focus areas include Life Sciences, Pain Management, Drugs and Neuropathic Pain.
Company details
Therapix Biosciences was founded in 2014 in Givatayim, Israel, within the biotechnology sector. Operations center on drug development for central nervous system disorders, utilizing an intellectual property portfolio of cannabinoid drugs and novel delivery systems. The pipeline features two programs: Brain Bright, a synthetic cannabinoid therapy for brain-related conditions, and a treatment for Tourette Syndrome based on the entourage effect, which has received orphan drug designation.
- Headquarters Givatayim, Israel
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website therapixbio.com
- Social LinkedIn X Facebook
- Acquired by FSD Pharma (Oct 2018)
- Latest Funding Round$8.15M (USD), Post-IPO
Mar 2021
- Investors
- Acquired byFSD Pharma
(Oct 2018)
Funding Insights of Therapix Biosciences
- Total Rounds 3
- Last Round Post-IPO β $8.15M
- First Round $2.25M
(Apr 2019)
All 3 funding rounds of Therapix Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $8.15M | Post-IPO | β | β | β |
| Jun 2020 | $2.6M | Post-IPO | β | β | β |
| Apr 2019 | $2.25M | Post-IPO | β | β | β |
1 investors in total: 1 institutional.
Investors in Therapix Biosciences
Therapix Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include FSD Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cannabis company engaged in cultivation, processing, and manufacturing related activities | 2018 | fsdpharma.com | Cobourg, Canada |
Investor details for Therapix Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Therapix Biosciences
4 people are tracked at Therapix Biosciences (4 in leadership).
| Name | Role | Group |
|---|---|---|
Amitay Weiss | CEO | Leadership |
Gilad Bar-lev | CEO & Board Member | Leadership |
Adi Zuloff-Shani | Chief Technology Officer | Leadership |
Oz Adler | CFO | Leadership |
Complete people profiles for Therapix Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Therapix Biosciences
5 dated milestones of Therapix Biosciences across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Therapix Biosciences is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by FSD Pharma.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Post-IPO, of $8.2M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Therapix Biosciences
Complete news archive for Therapix Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Therapix Biosciences
Therapix Biosciences was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Therapix Biosciences is headquartered in Givatayim, Israel. It is registered at Givatayim, Tel Aviv District, Israel.
Amitay Weiss is the CEO of Therapix Biosciences, as recorded in our data.
Therapix Biosciences was founded in 2014 in Givatayim, Israel, within the biotechnology sector. Operations center on drug development for central nervous system disorders, utilizing an intellectual property portfolio of cannabinoid drugs and novel delivery systems. The pipeline features two programs: Brain Bright, a synthetic cannabinoid therapy for brain-related conditions, and a treatment for Tourette Syndrome based on the entourage effect, which has received orphan drug designation.
Therapix Biosciences has 1 investor. Key investors include FSD Pharma.
Yes. Therapix Biosciences was acquired by FSD Pharma in October 2018.

